GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (TSE:4503) » Definitions » EPS (Diluted)

Astellas Pharma (TSE:4503) EPS (Diluted) : 円0.36 (TTM As of Dec. 2023)


View and export this data going back to 1949. Start your Free Trial

What is Astellas Pharma EPS (Diluted)?

Astellas Pharma's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was 円8.06. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was 円0.36.

Astellas Pharma's EPS (Basic) for the three months ended in Dec. 2023 was 円8.09. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was 円0.55.

Astellas Pharma's EPS without NRI for the three months ended in Dec. 2023 was 円7.91. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was 円-3.80.

During the past 12 months, Astellas Pharma's average EPS without NRIGrowth Rate was -105.10% per year. During the past 3 years, the average EPS without NRIGrowth Rate was -19.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was -12.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was 4.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Astellas Pharma's highest 3-Year average EPS without NRI Growth Rate was 89.70% per year. The lowest was -52.80% per year. And the median was 7.50% per year.


Astellas Pharma EPS (Diluted) Historical Data

The historical data trend for Astellas Pharma's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma EPS (Diluted) Chart

Astellas Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 114.94 104.08 64.90 67.05 54.09

Astellas Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.55 -25.31 18.42 -0.81 8.06

Competitive Comparison of Astellas Pharma's EPS (Diluted)

For the Drug Manufacturers - General subindustry, Astellas Pharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's PE Ratio falls into.



Astellas Pharma EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Astellas Pharma's Diluted EPS for the fiscal year that ended in Mar. 2023 is calculated as

Diluted EPS (A: Mar. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(98714-0)/1825.061
=54.09

Astellas Pharma's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(14513-0)/1800.620
=8.06

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Astellas Pharma  (TSE:4503) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Astellas Pharma EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Astellas Pharma (TSE:4503) Business Description

Traded in Other Exchanges
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.

Astellas Pharma (TSE:4503) Headlines

No Headlines